Amyloid Plaque
-
{
- All
- News
-
What I Tell Families When They Ask: Should We Put My Parent On The New Drug, Lormalzi?
Lormalzi is not a cure. I say this not to take away hope, but because understanding this is what allows families to make decisions rooted in reality rather than desperation.
-
Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks
Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explain who may benefit, who should avoid it, and the risks involved.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
Study Reveals A New Sound Therapy Could Offer Hope In Alzheimer's Treatment
This study builds upon previous research on 40 Hz frequencies, known as gamma waves.
-
Weak Internal Body Clock Linked To Higher Dementia Risk, Says New Study
"Disruptions in circadian rhythms may alter body processes like inflammation, and may interfere with sleep, possibly increasing amyloid plaques linked to dementia, or reducing amyloid clearance from the brain," says new study.
-
Lack of Sleep May Lead to Alzheimer's Disease
A new study, published in the journal Neurology,shows that poor sleep may have some serious consequences like increasing your risk for developing Alzheimer's disease.
-
Alzheimer's Drug That Shows Anti-Ageing Effects
An experimental drug aimed at combating Alzheimer's disease has a host of unexpected anti-ageing effects in animals, a new study says.
-
New Gene Linked to Alzheimer's Disease Identified
Researchers, including one of Indian-origin, have discovered an immune system gene associated with higher rates of amyloid plaque, a hallmark of Alzheimer's disease.
-
What I Tell Families When They Ask: Should We Put My Parent On The New Drug, Lormalzi?
Lormalzi is not a cure. I say this not to take away hope, but because understanding this is what allows families to make decisions rooted in reality rather than desperation.
-
Who Should Take Lormalzi? Alzheimer's Expert Explains Benefits And Risks
Neurologists say Lormalzi (donanemab), India's newly launched Alzheimer's therapy, may help slow cognitive decline in carefully selected patients with early disease. Experts explain who may benefit, who should avoid it, and the risks involved.
-
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly therapy targets amyloid plaques and may help slow cognitive decline in eligible patients with mild symptoms.
-
Study Reveals A New Sound Therapy Could Offer Hope In Alzheimer's Treatment
This study builds upon previous research on 40 Hz frequencies, known as gamma waves.
-
Weak Internal Body Clock Linked To Higher Dementia Risk, Says New Study
"Disruptions in circadian rhythms may alter body processes like inflammation, and may interfere with sleep, possibly increasing amyloid plaques linked to dementia, or reducing amyloid clearance from the brain," says new study.
-
Lack of Sleep May Lead to Alzheimer's Disease
A new study, published in the journal Neurology,shows that poor sleep may have some serious consequences like increasing your risk for developing Alzheimer's disease.
-
Alzheimer's Drug That Shows Anti-Ageing Effects
An experimental drug aimed at combating Alzheimer's disease has a host of unexpected anti-ageing effects in animals, a new study says.
-
New Gene Linked to Alzheimer's Disease Identified
Researchers, including one of Indian-origin, have discovered an immune system gene associated with higher rates of amyloid plaque, a hallmark of Alzheimer's disease.
